Click Therapeutics, a New York-based developer of prescription digital therapeutics, has raised $50M in Series D funding led by Boehringer Ingelheim Venture Fund. The company builds evidence-based software delivered via smartphones to treat diseases with neurological or behavioral components, such as major depressive disorder and schizophrenia. The capital, paired with a strategic agreement, will fund commercialization of CT-155, an FDA-designated Breakthrough Device for schizophrenia negative symptoms, after Boehringer transferred full rights to Click.
Big Health Raise Signals DTx Momentum
The round arrives as digital therapeutics funding rebounds, with Big Health securing $24M in February 2026 for its mental health programs. Click's prior FDA authorizations for Rejoyn in depression, AspyreRx for type 2 diabetes, and CT-132 for episodic migraine position it ahead in a sector maturing post-Pear Therapeutics' bankruptcy. Boehringer's investment underscores pharma confidence in Click's platform for adjunct therapy to drugs.
Schizophrenia Negative Symptoms Go Untreated
Negative symptoms affect most schizophrenia patients, yet no FDA-approved treatments exist, leaving a gap in standard antipsychotic regimens. Phase 3 CONVOKE trial data showed CT-155 delivered a 6.8-point improvement in symptom severity, a 62% relative gain over control with strong safety. This addresses behavioral deficits like motivation loss that drive poor outcomes and high costs.
Platform Powers Multi-Indication PDTs
Click's proprietary Click Neurobehavioral Intervention platform uses AI, neuroscience, and patient-centric design for just-in-time adaptive interventions via mobile apps. Unlike single-focus rivals like Akili Interactive's $252M-funded EndeavorRx for ADHD, Click spans psychiatry, migraine, diabetes, and more with three FDA-cleared products. Recent acquisition of Better Therapeutics assets bolsters its cardiometabolic reach.
AI Engagement Boosts Adherence
Features like Clickometrics AI track engagement, achieving 70-88% adherence in trials versus typical drop-offs. Partnerships integrate with pharma, as in Rejoyn with Otsuka and now CT-155 from Boehringer. The approach combines PDTs with drugs via Click SE Software-Enhanced Drugs for superior outcomes.
Boehringer CVC Drives Commercial Shift
Boehringer Ingelheim Venture Fund, with a €350M evergreen fund and 70+ investments, leads as strategic validation after co-developing CT-155. The deal transfers commercialization rights, signaling Click's readiness to launch post-Phase 3 success. This aligns with BIVF's digital health thesis, including adherence plays like Wellth.
DTx Market Scales to $32B
The global digital therapeutics market stood at $6.22B in 2023 and projects to reach $32.52B by 2030 at 27.77% CAGR, per Grand View Research. Competitors like Omada Health ($456M total) target cardiometabolic via coaching, while Click emphasizes standalone prescription software. FDA PDURS guidance enables drug-software combos, fueling pharma partnerships.
Founder Exits Fuel Biotech Spinouts
CEO David Benshoof Klein founded Click after leading Opus Point Partners, spinning out firms with exits like Cougar Biotechnology to J&J and Chelsea Therapeutics to Lundbeck. Co-founder Bruce Leuchter brings neuropsychiatry MD expertise from Weill Cornell. This track record de-risks Click's path from R&D to multiple FDA wins and pharma deals.
Commercial Hires Target 2026 Launches
Click plans hiring for CT-132 migraine commercialization, including a Lead Product Manager, alongside an Information Security Lead for regulated scaling. Recent Ultrahuman partnership adapts CT-132 to smart rings for biomarker-driven migraine tools. With CT-155 rights secured, focus shifts to FDA clearance and market entry.